Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)

Recruiting
100 years or below
All
1 Location

Brief description of study

The primary objective is to estimate and compare overall survival between the two arms:  patients who are Very Likely to find a MUD versus those who are Very Unlikely to find  a MUD.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Hodgkin Lymphoma,Anaplastic Astrocytoma,Acute Myeloid Leukemia,Myelodysplatic syndromes,Hodgkin's Lymphoma,Acute Lymphoblastic Leukemia,Sickle Cell Disease
  • Age: 100 years or below
  • Gender: All

Inclusion Criteria

Patients of all ages with AML, ALL, MDS, NHL, HL, AA, or SCD are eligible.

Any planned conditioning regimen and GVHD prophylaxis approach is eligible.

Patients must be considered suitable allogeneic transplant candidates at the time of enrollment based on medical history, physical examination, and available laboratory tests. Specific testing for organ function is not required for eligibility but, if available, these tests should be used by the treating physician to judge transplant suitability.

Patient and physician must intend to proceed with allogeneic HCT within the next 6 months if a suitable donor is identified.

Updated on 04 Aug 2024. Study ID: 1904367480 (BMTCTN1702)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team